Literature DB >> 26083568

Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.

Yue Yang1, C Dirk Keene, Elaine R Peskind, Douglas R Galasko, Shu-Ching Hu, Eiron Cudaback, Angela M Wilson, Ge Li, Chang-En Yu, Kathleen S Montine, Jing Zhang, Geoffrey S Baird, Bradley T Hyman, Thomas J Montine.   

Abstract

Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) β42-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE ε4/ε4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE ε3/ε3 or APOE ε3/ε4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and β-amyloid (Aβ42)-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26083568      PMCID: PMC4471879          DOI: 10.1097/NEN.0000000000000207

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  130 in total

1.  Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein.

Authors:  M Lindh; M Blomberg; M Jensen; H Basun; L Lannfelt; B Engvall; H Scharnagel; W März; L O Wahlund; R F Cowburn
Journal:  Neurosci Lett       Date:  1997-06-27       Impact factor: 3.046

Review 2.  Flow cytometric analysis of circulating microparticles in plasma.

Authors:  Aaron F Orozco; Dorothy E Lewis
Journal:  Cytometry A       Date:  2010-06       Impact factor: 4.355

3.  Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.

Authors:  Sophie Sokolow; Sanh H Luu; Karabi Nandy; Carol A Miller; Harry V Vinters; Wayne W Poon; Karen H Gylys
Journal:  Neurobiol Dis       Date:  2011-09-03       Impact factor: 5.996

4.  Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter.

Authors:  O Chambenoit; Y Hamon; D Marguet; H Rigneault; M Rosseneu; G Chimini
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

5.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.

Authors:  H F Heijnen; A E Schiel; R Fijnheer; H J Geuze; J J Sixma
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

6.  Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants.

Authors:  B Permanne; C Perez; C Soto; B Frangione; T Wisniewski
Journal:  Biochem Biophys Res Commun       Date:  1997-11-26       Impact factor: 3.575

7.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

8.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Authors:  K Blennow; C Hesse; P Fredman
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

9.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

Review 10.  Extracellular vesicles: emerging targets for cancer therapy.

Authors:  Pieter Vader; Xandra O Breakefield; Matthew J A Wood
Journal:  Trends Mol Med       Date:  2014-04-03       Impact factor: 11.951

View more
  15 in total

Review 1.  Extracellular vesicles and intercellular communication within the nervous system.

Authors:  Valentina Zappulli; Kristina Pagh Friis; Zachary Fitzpatrick; Casey A Maguire; Xandra O Breakefield
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

Review 2.  The effect of aging on brain barriers and the consequences for Alzheimer's disease development.

Authors:  Nina Gorlé; Caroline Van Cauwenberghe; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mamm Genome       Date:  2016-05-03       Impact factor: 2.957

3.  Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4.

Authors:  Nadia Postupna; Caitlin S Latimer; Eric B Larson; Emily Sherfield; Julie Paladin; Carol A Shively; Matthew J Jorgensen; Rachel N Andrews; Jay R Kaplan; Paul K Crane; Kathleen S Montine; Suzanne Craft; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2017-02-16       Impact factor: 4.307

Review 4.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

5.  Assessment of separation methods for extracellular vesicles from human and mouse brain tissues and human cerebrospinal fluids.

Authors:  Satoshi Muraoka; Weiwei Lin; Mei Chen; Samuel W Hersh; Andrew Emili; Weiming Xia; Tsuneya Ikezu
Journal:  Methods       Date:  2020-02-05       Impact factor: 3.608

6.  Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying α-Synuclein-Containing Extracellular Vesicles.

Authors:  Zhen Hong; Chen Tian; Tessandra Stewart; Patrick Aro; David Soltys; Matt Bercow; Lifu Sheng; Kayla Borden; Tarek Khrisat; Catherine Pan; Cyrus P Zabetian; Elaine R Peskind; Joseph F Quinn; Thomas J Montine; Jan Aasly; Min Shi; Jing Zhang
Journal:  Neurology       Date:  2021-03-23       Impact factor: 9.910

Review 7.  Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases.

Authors:  Ji-Young Choi; Sujin Kim; Hyo-Bum Kwak; Dong-Ho Park; Jae-Hyoung Park; Jeong-Seon Ryu; Chang-Shin Park; Ju-Hee Kang
Journal:  Int Neurourol J       Date:  2017-06-21       Impact factor: 2.835

8.  DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA.

Authors:  Hussein N Yassine; Etienne Croteau; Varun Rawat; Joseph R Hibbeln; Stanley I Rapoport; Stephen C Cunnane; John C Umhau
Journal:  Alzheimers Res Ther       Date:  2017-03-23       Impact factor: 6.982

Review 9.  Extracellular Vesicles and a Novel Form of Communication in the Brain.

Authors:  Manuela Basso; Valentina Bonetto
Journal:  Front Neurosci       Date:  2016-03-31       Impact factor: 4.677

Review 10.  Extracellular Vesicles in Physiology, Pathology, and Therapy of the Immune and Central Nervous System, with Focus on Extracellular Vesicles Derived from Mesenchymal Stem Cells as Therapeutic Tools.

Authors:  Sylwia Koniusz; Anna Andrzejewska; Maurizio Muraca; Amit K Srivastava; Miroslaw Janowski; Barbara Lukomska
Journal:  Front Cell Neurosci       Date:  2016-05-02       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.